BridgeBio (BBIO) director sells 1,641 shares at $65 under 10b5-1

Q: What did BridgeBio (BBIO) disclose in this Form 4?

A director sold 1,641 shares of common stock on 10/27/2025 at $65 per share under a Rule 10b5-1 plan.

Q: How many BBIO shares does the reporting person hold after the sale?

Reported holdings are 878,338 shares indirectly via a trust and 83,275 shares directly.

Q: Was the BBIO trade under a 10b5-1 plan?

Yes. The filing states the sale was under a Rule 10b5-1 plan adopted on August 28, 2024.

Q: What is the relationship of the filer to BridgeBio (BBIO)?

The filer is listed as a Director of the company.

Q: Is the ownership direct or through an entity?

Both. 878,338 shares are held indirectly by the Francis P. McCormick Rev Trust, and 83,275 shares are held directly.

BridgeBio Pharma (BBIO): Director transaction reported.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.

Insider Trade Summary

Net Seller: 1,641 shares

Net Sell 2 txns

Insider MCCORMICK FRANK

Role Director

Sold 1,641 shs ($107K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,641	$65.00	$107K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 878,338 shares (Indirect, By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017); Common Stock — 83,275 shares (Direct)

Footnotes (1)

F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio (BBIO) disclose in this Form 4?

A director sold 1,641 shares of common stock on 10/27/2025 at $65 per share under a Rule 10b5-1 plan.

How many BBIO shares does the reporting person hold after the sale?

Reported holdings are 878,338 shares indirectly via a trust and 83,275 shares directly.

Was the BBIO trade under a 10b5-1 plan?

Yes. The filing states the sale was under a Rule 10b5-1 plan adopted on August 28, 2024.

What was the price for the BBIO shares sold?

The reported sale price was $65 per share.

What is the relationship of the filer to BridgeBio (BBIO)?

The filer is listed as a Director of the company.

Is the ownership direct or through an entity?

Both. 878,338 shares are held indirectly by the Francis P. McCormick Rev Trust, and 83,275 shares are held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/29/2025 - 05:10 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCORMICK FRANK

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/27/2025		S⁽¹⁾		1,641	D	$65	878,338	I	By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Common Stock								83,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR